EHA 2022 | Novel agents of interest for the treatment of BPDCN
In this video, Marco Herling, MD, University of Leipzig, Leipzig, Germany, shares some insights into novel agents of interest for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN). Dr Herling first highlights the use of tagraxofusp and venetoclax, and further discusses different combination approaches for patients and the potential use of CAR-T therapy. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
Transcript (edited for clarity)
One of the leading centers investigating novel agents is the MD Anderson Cancer Center and many studies come from there and I can say that the main substance classes besides targeting CD123 via tagraxofusp are demethylating agents, venetoclax as a BCL-2 inhibitor and… Let’s say people play with these combinations. For young fit patients that are eligible for later on consolidating allogeneic stem cell transplantation, people at MD Anderson and elsewhere try to go all in with all the available substances in an approach that one could call total therapy, venetoclax plus, I perceive it as a U...
One of the leading centers investigating novel agents is the MD Anderson Cancer Center and many studies come from there and I can say that the main substance classes besides targeting CD123 via tagraxofusp are demethylating agents, venetoclax as a BCL-2 inhibitor and… Let’s say people play with these combinations. For young fit patients that are eligible for later on consolidating allogeneic stem cell transplantation, people at MD Anderson and elsewhere try to go all in with all the available substances in an approach that one could call total therapy, venetoclax plus, I perceive it as a U.S. American based poly-chemotherapy, plus tagraxofusp as a targeted agent. For the not so fit patients we have demethylating agents like decitabine, or Vidaza, plus venetoclax or plus tagraxofusp, the mentioned fusion protein targeting CD123.
We also have maintenance concepts after an allogeneic transplant, which addresses relapses that frequently occur, maintenance with tagraxofusp for example, and we have very innovative approaches with other CD123-targeting agents. Immunogen’s 632, which is pretty much also a fusion protein targeting CD123 but replacing the diphtheria toxin-bound alkylating agent hoping that the capillary leak syndrome, one of the side effects of tagraxofusp, will be spared by that approach. And another approach of course, is CD123-targeting CAR T-cells. So we are looking forward to see the results coming from these trials that are taking place in the U.S. as well as in Europe.
Read more...
